Concepedia

Sarah Nuyens

SN

Statistics

Publications

8

Citations

1K

H-Index

8

Active since

2013

Affiliations

European Organisation for Research and Treatment of Cancer(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

KU Leuven

Erasmus MC Cancer Institute

University of Zurich

Sarah Nuyens is an author at European Organisation for Research and Treatment of Cancer specializing in pharmacology, oncology, and medicine.

Publications per year

2013–2024

8

Publications

8

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 397 citations · Full text

, , +17

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick et al. · The Lancet Oncology · 2021 · 327 citations · Full text

, , +16

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Martin J. van den Bent, Marica Eoli, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2019 · 189 citations · Full text

, , +17

Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial

Patrick Roth, Thierry Gorlia, Jaap C. Reijneveld et al. · Neuro-Oncology · 2024 · 47 citations · Full text

, , +15

Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma

Paul M. Clément, Linda Dirven, Marica Eoli et al. · European Journal of Cancer · 2021 · 19 citations · Full text

, , +17

1–5 of 8